OXFORD
FINANCE

Oxford Finance's Leveraged Lending Group 2024 Year-To-Date Update

~$700MM in New Capital Commitments and Fundings
7 New Platform Transactions
2 Credit Facility Upsizes

The first half of 2024 saw a modest pickup in M&A market activity relative to last year, but volume remained lower than in 2021 and 2022. Debt capital markets appear to have fully reopened with aggressive terms.

Oxford's Leveraged Lending Group continued to execute on opportunities for new and existing clients. In addition to the firm's historical focus on healthcare services, we expanded our industry coverage to include business services & technology sectors. In the YTD period, the Group closed on ~$600 million in new capital commitments to support leveraged buyouts and debt recapitalizations. New platform investments were made alongside five new private equity relationships as well as with several repeat sponsor clients. The Group also funded over $100 million to existing borrowers for M&A and other growth initiatives.

SELECT TRANSACTIONS IN 2024:

Get Well

June 2024: Oxford acted as the administrative agent in the funding of a senior credit facility to finance the acquisition by SAI Group of a leading patient engagement solutions provider to healthcare organizations.

KASHI
CLINICAL
LABORATORIES

June 2024: Oxford acted as the administrative agent in the funding of a new senior credit facility to finance the majority recapitalization of a specialty lab services provider for pre- and post-transplant procedures and other diagnostics by Prairie Capital.

TARRYTOWN
EXPOCARE PHARMACY

May 2024: Oxford acted as the administrative agent in the upsize of an existing senior credit facility to support growth initiatives for an institutional, long-term care pharmacy servicing intellectually and developmentally disabled patients backed by Sheridan Capital Partners.

ASCEND VISION
PARTNERS

April 2024: Oxford acted as the administrative agent in the funding of a senior credit facility to refinance debt and support growth initiatives at a practice management platform focused on ophthalmology and optometry backed by Chicago Pacific Founders.

Oxford is the principal lender or principal co-lender in each transaction Loans made or arranged pursuant to a California Financing Law License.

SELECT TRANSACTIONS IN 2024 - CONTINUED:

April 2024: Oxford acted as the administrative agent in the funding of a senior credit facility to refinance debt and support growth initiatives for a leading franchisor and provider of mental health services backed by Princeton Equity Group.

April 2024: Oxford acted as the administrative agent in the funding of a senior credit facility to finance the majority recapitalization of a leading third-party administrator and cost containment solutions provider to self-insured employers by Gauge Capital.

Oxford Finance's Leveraged Lending Team

Peter Dahms
Managing Director
Phone: 201.844.9541
pdahms@oxfordfinance.com

Tanzeer Khan
Managing Director
Phone: 858.750.2657
tkhan@oxfordfinance.com

Ajay Nanda
Senior Director
Phone: 201.899.4075
ananda@oxfordfinance.com

Sunil Annapareddy
Senior Director
Phone: 917.551.5075
sannapareddy@oxfordfinance.com

Mark Hirsh
Senior Director
Phone: 858.500.3646
mhirsh@oxfordfinance.com

Kush Patel
Senior Director
Phone: 858.529.5214
kpatel@oxfordfinance.com

ABOUT OXFORD FINANCE

Investment Criteria

- Sponsored & Non-Sponsored
- Loan Sizes: $20MM to $200MM
- EBITDA: $5MM to $50MM
- Headquartered in the United States
- Lead Arranger or Club Participant

Products

- Revolvers
- Senior & Unitranche Term Loans
- Delayed Draw Term Loans
- 2nd Lien / Last Out / Mezzanine
- Full Capital Markets Capability

Why Oxford?

- Flexible Structures
- Quick and Efficient Execution
- Predictable and Reliable Partner
- Multi-Decade Operating History

Oxford is the principal lender or principal co-lender in each transaction Loans made or arranged pursuant to a California Financing Law License.